The Department of Veterans Affairs intends to issue a solicitation for the preparation and characterization of specialized liposomal formulations incorporating patented joint targeting technologies for arthritis therapy. The work involves producing research-grade liposomes with a patented lipid composition, a joint targeting peptide (ART2), and an encapsulated anti-arthritis drug, along with standard physicochemical characterization. Contractors must demonstrate capability in custom liposome formulation, peptide functionalization, drug encapsulation, and analytical characterization. A Confidential Disclosure Agreement (CDA) with the VA Technology Transfer Program is required before any proprietary technical specifications are released. The location for performance of services is not specified, and no budget amounts are mentioned.

The Department of Veterans Affairs is seeking qualified vendors to produce specialized liposomal formulations incorporating patented joint-targeting technologies for arthritis therapy. Vendors must demonstrate capability in custom liposome or nanoparticle formulation, peptide functionalization, drug encapsulation, and nanoparticle characterization. Performance of services is not specified, but work involves research-grade formulations for non-GLP exploratory studies. No budget amount is provided. Responses are due by July 29, 2026, and a signed Confidential Disclosure Agreement is required before proprietary technical details are shared.